Gastrointestinal dysmotility in rodent models of Parkinson's disease

被引:1
|
作者
Pellegrini, Carolina [1 ]
Travagli, R. Alberto [2 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Unit Histol & Med Embryol, Pisa, Italy
[2] Neurobiol Res, Newport, NC USA
关键词
animal models; enteric nervous system; gastrointestinal symptoms; gut microbiota; Parkinson's disease; ENTERIC DOPAMINERGIC-NEURONS; 6-HYDROXYDOPAMINE RAT MODEL; DETECT LEWY PATHOLOGY; NIGRA PARS COMPACTA; MPTP MOUSE MODEL; ALPHA-SYNUCLEIN; GASTRIC DYSMOTILITY; INTESTINAL MOTILITY; NERVOUS-SYSTEM; VAGAL PATHWAY;
D O I
10.1152/ajpgi.00225.2023
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Multiple studies describe prodromal, nonmotor dysfunctions that affect the quality of life of patients who subsequently develop Parkinson's disease (PD). These prodromal dysfunctions comprise a wide array of autonomic issues, including severe gastrointestinal (GI) motility disorders such as dysphagia, delayed gastric emptying, and chronic constipation. Indeed, strong evidence from studies in humans and animal models suggests that the GI tract and its neural, mainly vagal, connection to the central nervous system (CNS) could have a major role in the etiology of PD. In fact, misfolded alpha-synuclein aggregates that form Lewy bodies and neurites, i.e., the histological hallmarks of PD, are detected in the enteric nervous system (ENS) before clinical diagnosis of PD. The aim of the present review is to provide novel insights into the pathogenesis of GI dysmotility in PD, focusing our attention on functional, neurochemical, and molecular alterations in animal models.
引用
下载
收藏
页码:G345 / G359
页数:15
相关论文
共 50 条
  • [31] The prevalence and patterns of oesophageal dysmotility in patients with Parkinson's disease
    Sung, H. -Y.
    Choi, M. -G.
    Kim, J. -S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 555 - 555
  • [32] Developmental origins of Parkinson disease: Improving the rodent models
    Jimenez-Salvador, Irene
    Meade, Patricia
    Iglesias, Eldris
    Bayona-Bafaluy, Pilar
    Ruiz-Pesini, Eduardo
    AGEING RESEARCH REVIEWS, 2023, 86
  • [33] Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios
    Hubbard, David
    Hacksell, Uli
    McFarland, Krista
    BEHAVIOURAL PHARMACOLOGY, 2013, 24 (07): : 628 - 632
  • [34] LY503430: Pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease
    O'Neill, MJ
    Murray, TK
    Clay, MP
    Lindstrom, T
    Yang, CR
    Nisenbaum, ES
    CNS DRUG REVIEWS, 2005, 11 (01): : 77 - 96
  • [35] Oscillatory Activity and Synchronization in the Basal Ganglia Network in Rodent Models of Parkinson's Disease
    Walters, Judith R.
    Tierney, Patrick L.
    Bergstrom, Debra A.
    BASAL GANGLIA IX, 2009, 58 : 443 - 459
  • [36] Versatile guardians: regenerative regulatory T cells in Parkinson's disease rodent models
    Ip, Chi Wang
    Wischhusen, Joerg
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [37] Studies of the neural mechanisms of deep brain stimulation in rodent models of Parkinson's disease
    Chang, Jing-Yu
    Shi, Li-Hong
    Luo, Fei
    Zhang, Wang-Ming
    Woodward, Donald J.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2008, 32 (03): : 352 - 366
  • [38] Studies of the neural mechanisms of deep brain stimulation in rodent models of Parkinson's disease
    Chang, Jing-Yu
    Shi, Li-Hong
    Luo, Fel
    Zhang, Wang-Ming
    Woodward, Donald J.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2007, 31 (05): : 643 - 657
  • [39] Current and Emerging MR Methods and Outcome in Rodent Models of Parkinson's Disease: A Review
    Petiet, Alexandra
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [40] Mu opioid receptor binding in the basal ganglia in rodent models of Parkinson's disease
    Begum, S
    Brotchie, JM
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 198 - 198